- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CARsgen Therapeutics Holdings Ltd (2171)
CARsgen Therapeutics Holdings Ltd stock price live, this page displays HK 2171 stock exchange data. View the 2171 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CARsgen Therapeutics Holdings Ltd real time stock price chart below.
What Is the CARsgen Therapeutics Holdings Ltd Stock Price Today?
The CARsgen Therapeutics Holdings Ltd stock price today is 22.70.
What Is the Stock Symbol for CARsgen Therapeutics Holdings Ltd?
The stock symbol for CARsgen Therapeutics Holdings Ltd is ""2171.""
What Stock Exchange Does CARsgen Therapeutics Holdings Ltd Trade On?
CARsgen Therapeutics Holdings Ltd is listed and trades on the Hong Kong stock exchange.
Is CARsgen Therapeutics Holdings Ltd a Good Stock to Buy?
Determining whether CARsgen Therapeutics Holdings Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2171 quote. (ISIN: KYG1996C1006)
What Is the CARsgen Therapeutics Holdings Ltd Stock Price Today?
The CARsgen Therapeutics Holdings Ltd stock price today is 22.70.
What Is the Stock Symbol for CARsgen Therapeutics Holdings Ltd?
The stock symbol for CARsgen Therapeutics Holdings Ltd is ""2171.""
What Stock Exchange Does CARsgen Therapeutics Holdings Ltd Trade On?
CARsgen Therapeutics Holdings Ltd is listed and trades on the Hong Kong stock exchange.
Is CARsgen Therapeutics Holdings Ltd a Good Stock to Buy?
Determining whether CARsgen Therapeutics Holdings Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2171 quote. (ISIN: KYG1996C1006)
Hong Kong
Currency in HKD
22.70
+1.52(+7.18%)
Closed·
Fair Value
An estimate of a CARsgen Therapeutics Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.94
22.98
52 wk Range
2.48
25.60
2171 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
2171 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a CARsgen Therapeutics Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.9422.98
52 wk Range
2.4825.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2171 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a CARsgen Therapeutics Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
22.17
Downside
-2.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
CARsgen Therapeutics Holdings Ltd Company Profile
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. The company was founded in 2014 and is headquartered in Shanghai, China.
Compare 2171 to Peers and Sector
Metrics to compare | 2171 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2171PeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.2x | −29.0x | −0.5x | |
PEG Ratio | −0.92 | 0.25 | 0.00 | |
Price/Book | 11.5x | 6.4x | 2.6x | |
Price / LTM Sales | 131.7x | 19.8x | 3.3x | |
Upside (Analyst Target) | −0.3% | −5.3% | 40.1% | |
Fair Value Upside | Unlock | −20.2% | 5.1% | Unlock |
Analyst Ratings
1 Buy
0 Hold
1 Sell
Ratings:
2 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 22.17
(-2.33% Downside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.14 / -0.54
Revenue / Forecast
50.96M / --
FAQ
What Stock Exchange Does CARsgen Therapeutics Holdings Trade On?
CARsgen Therapeutics Holdings is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for CARsgen Therapeutics Holdings?
The stock symbol for CARsgen Therapeutics Holdings is "2171."
What Is the CARsgen Therapeutics Holdings Market Cap?
As of today, CARsgen Therapeutics Holdings market cap is 12.57B.
What Is CARsgen Therapeutics Holdings's Earnings Per Share (TTM)?
The CARsgen Therapeutics Holdings EPS (TTM) is -0.95.
From a Technical Analysis Perspective, Is 2171 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has CARsgen Therapeutics Holdings Stock Split?
CARsgen Therapeutics Holdings has split 0 times.
How Many Employees Does CARsgen Therapeutics Holdings Have?
CARsgen Therapeutics Holdings has 371 employees.
What is the current trading status of CARsgen Therapeutics Holdings (2171)?
As of 17 Aug 2025, CARsgen Therapeutics Holdings (2171) is trading at a price of 22.70, with a previous close of 21.18. The stock has fluctuated within a day range of 20.94 to 22.98, while its 52-week range spans from 2.48 to 25.60.
What Is CARsgen Therapeutics Holdings (2171) Price Target According to Analysts?
The average 12-month price target for CARsgen Therapeutics Holdings is HKD22.17118884, with a high estimate of HKD29.10864117 and a low estimate of HKD15.23373652. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -2.33% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.